Get the Stockscreener App
125.02
0.14%
-0.18
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $125.02, with a volume of 6.60M.
It is down -0.14% in the last 24 hours and up +5.52% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$125.20
Open:
$124.81
24h Volume:
6.60M
Relative Volume:
0.96
Market Cap:
$155.13B
Revenue:
$29.05B
Net Income/Loss:
$8.11B
P/E Ratio:
19.36
EPS:
6.4563
Net Cash Flow:
$9.16B
1W Performance:
+5.20%
1M Performance:
+5.52%
6M Performance:
+27.08%
1Y Performance:
+35.73%
1-Day Range:
$122.50
$125.64
1-Week Range:
$117.13
$127.68
52-Week Range:
$86.08
$127.68
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
125.02 | 155.33B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,025.28 | 915.49B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
195.93 | 470.41B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
232.36 | 410.55B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.26 | 253.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
92.92 | 230.65B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Gilead Sciences, Inc. (GILD)’s Mixed Quarter Draws Divergent Analyst Views - Insider Monkey
Needham & Company LLC Increases Gilead Sciences (NASDAQ:GILD) Price Target to $140.00 - MarketBeat
Daiwa Capital Markets Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Gilead Sciences (NASDAQ:GILD) Coverage Initiated at Scotiabank - MarketBeat
Wealth Alliance LLC Has $1.16 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Impax Asset Management Group plc - MarketBeat
Police & Firemen s Retirement System of New Jersey Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead scores clinical trial win toward moving HIV patients from multiple-drug regimen to single tablet - The Business Journals
Gilead Sciences, Inc. $GILD Shares Sold by M&G PLC - MarketBeat
Gilead Looks To Simplify HIV Treatment By Combining Two Leading Drugs in One Pill - BioSpace
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal - TradingView
Gilead’s HIV single-pill combo meets primary endpoints in pivotal trial - Yahoo
Is Gilead’s Successful Phase 3 HIV Regimen Trial Shifting the Investment Case for GILD? - Yahoo Finance
Is Gilead Sciences Inc. (GIS) stock inflation resilientTreasury Yields & Risk Managed Investment Strategies - Fundação Cultural do Pará
Credit Capital Investments LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Candriam S.C.A. - MarketBeat
Gilead Sciences Insider Sold Shares Worth $6,590,487, According to a Recent SEC Filing - MarketScreener
Gilead Sciences EVP Telman sells $6.59 million in stock By Investing.com - Investing.com Nigeria
Gilead’s Experimental One Pill Regimen Proved Non-Inferior To Multi-Pill Regimens In Treating HIV - Stocktwits
Gilead Sciences EVP Telman sells $6.59 million in stock - Investing.com India
Can Gilead Sciences Inc. stock continue upward trendJuly 2025 Action & Pattern Based Trade Signal System - newser.com
Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV-1 treatment meets primary endpoint in Phase 3 ARTISTRY-1 trial - European AIDS Treatment Group
Scotiabank Initiates Coverage of Gilead Sciences (GILD) with Sector Outperform Recommendation - Nasdaq
Needham Maintains Gilead Sciences (GILD) Buy Recommendation - Nasdaq
Gilead Sciences (NASDAQ:GILD) Hits New 1-Year HighHere's What Happened - MarketBeat
Will Gilead Sciences Inc. (GIS) stock outperform energy sector in 2025Market Activity Report & Risk Controlled Daily Trade Plans - newser.com
Gilead says single-tablet option matches complex HIV regimens in Phase III study - FirstWord Pharma
GILD's Price Target Raised by Needham to $140.00 | GILD Stock Ne - GuruFocus
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage TrialGilead Sciences (NASDAQ:GILD) - Benzinga
Gilead stock rises after positive HIV treatment trial results By Investing.com - Investing.com Canada
Gilead stock rises after positive HIV treatment trial results - Investing.com
Gilead Sciences (GILD) Achieves Key Milestone in HIV Treatment T - GuruFocus
Gilead Sciences’ Strategic Advancements in HIV Treatment Bolster Buy Rating and Future Revenue Prospects - TipRanks
Needham Adjusts Gilead Sciences Price Target to $140 From $133, Maintains Buy Rating - MarketScreener
Gilead hits late-stage trial win for new single-tablet HIV therapy - Seeking Alpha
What drives Gilead Sciences Inc GIS stock priceGap Fill Strategies & Stay Safe With Built-In Risk Monitoring - earlytimes.in
What drives Gilead Sciences Inc. stock priceGlobal Market Influence & Free Tap Rapid Wealth - earlytimes.in
Gilead hails phase 3 victory for single-tablet combo of bictegravir and lenacapavir, preps filings - Fierce Pharma
Gilead (GILD) Reveals Promising Phase 3 Trial Results for HIV Tr - GuruFocus
Gilead Reports Positive Phase 3 Results For Bictegravir/ Lenacapavir Single-tablet Regimen For HIV - Nasdaq
Gilead reports positive results for HIV single-tablet regimen By Investing.com - Investing.com Australia
Daiwa Securities Adjusts Gilead Sciences Price Target to $129 From $128, Maintains Outperform Rating - MarketScreener
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Can Gilead Stock Outrun Regeneron In The Next Rally? - Forbes
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial - Yahoo Finance
Geode Capital Management LLC Buys 727,515 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
United Asset Strategies Inc. Sells 2,099 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
KBC Group NV Raises Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead price attacks pivotal resistanceForecast today13-11-2025 - Economies.com
National Pension Service Sells 211,960 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gilead Sciences Inc Stock (GILD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Telman Deborah H | EVP, Corporate Affairs & GC |
Nov 12 '25 |
Sale |
122.85 |
53,646 |
6,590,487 |
43,676 |
1.83%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):